• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22475 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Infrared lasers for treating onychomycosis
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: OVA1™ test for the assessment of suspected ovarian cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Placental growth factor based tests for the diagnosis of pre-eclampsia
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: RealTime mS9 Colorectal Cancer (CRC) Assay for the early detection of colorectal cancer
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: RhinoChill® intranasal cooling device for protective cooling the brain after a cerebral ischaemic event
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: SoundBite™ hearing system
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: SpringTMS™ Total Migraine System
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: ThromboLUX™ for determining platelet quality
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: VERV™ patient managed transdermal neuromodulation system for overactive bladder syndrome
2012     NIHR Horizon Scanning Centre (NIHR HSC) UPDATED: Xpert MTB/RIF® test for tuberculosis
2007     Agency for Healthcare Research and Quality (AHRQ) Updating systematic reviews
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Upper airway stimulation for moderate-to-severe sleep apnea
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Upper Airway Stimulation for Moderate-to-Severe Sleep Apnea. 1st Update 2019
2022     Austrian Institute for Health Technology Assessment (AIHTA) Upper airway stimulation for moderate-to-severe sleep apnoea. Update 2022
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Upper extremity deep vein thrombosis with peripherally inserted central catheters: a review of the guidelines
2018     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Upper gastrointestinal endoscopy categorisation guidelines for adults
2008     HAYES, Inc. Upright magnetic resonance imaging (MRI) for diagnosis of spinal disorders
2014     HAYES, Inc. Upright magnetic resonance imaging for diagnosis of spinal disorders
2005     Institute for Clinical Evaluative Sciences (ICES) Uptake and outcomes associated with cyclooxygenase (COX-2) inhibitors in Ontario's elderly
1997     Scottish Health Purchasing Information Centre (SHPIC) Uptake of breast cancer screening
2011     Institute for Clinical Evaluative Sciences (ICES) Uptake of the new fee code for Ontario's enhanced 18-month well baby visit: a preliminary evaluation
1998     ECRI Urea breath tests for detecting helicobacter pylori
2007     HAYES, Inc. Ureteral bulking agents for vesicoureteral reflux disease
2014     Penn Medicine Center for Evidence-based Practice (CEP) Urinalysis and urine culture specimens taken from old versus new urinary catheters in patients with suspected urinary tract infection
2010     HAYES, Inc. Urinary cross-linked N-telopeptide of type I collagen biomarker for diagnosis of osteoporosis and fracture risk assessment
2010     HAYES, Inc. Urinary cross-linked N-telopeptide of type I collagen biomarker for management of osteoporosis treatment
2001     Health Council of the Netherlands Gezondheidsraad (GR) Urinary incontinence - review, expert panel
2006     National Institute for Health and Care Excellence (NICE) Urinary incontinence: the management of urinary incontinence in women
2008     Medical Services Advisory Committee (MSAC) Urinary metabolic profile
2008     Medical Services Advisory Committee (MSAC) Urinary metabolic profiling for detection of metabolic disorders
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Urine based testing for gonorrhea and chlamydia: a review of diagnostic accuracy, cost-effectiveness, and compliance
2013     Penn Medicine Center for Evidence-based Practice (CEP) Urine drug screening in chronic pain patients on opioid therapy
2010     Penn Medicine Center for Evidence-based Practice (CEP) Urine drug screening in chronic pain patients on opioid therapy
2023     Penn Medicine Center for Evidence-based Practice (CEP) Urine pregnancy screening for patients with and without the capacity for pregnancy
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Urine testing in long-term care: clinical and cost effectiveness
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Urine testing in long-term care: guidelines
2020     NIHR Health Technology Assessment programme Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT
2017     HAYES, Inc. Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2016     HAYES, Inc. UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2011     HAYES, Inc. UroLume urethral stent (American Medical Systems Inc.) for urinary obstruction secondary to benign prostatic hyperplasia (BPH)
2016     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ursodeoxycholic acid (Ursofalk®)
2020     Agency for Care Effectiveness (ACE) Ursodeoxycholic acid for treating primary biliary cirrhosis
2020     NIHR Health Technology Assessment programme Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT
2006     Adelaide Health Technology Assessment (AHTA) USCOM cardiac output monitor for patients requiring haemodynamic monitoring
2005     Adelaide Health Technology Assessment (AHTA) USCOM cardiac output monitor for ultrasonic cardiac output measurement in patients requiring haemodynamic monitoring
2006     Alberta Heritage Foundation for Medical Research (AHFMR) USCOM for cardiac output monitoring
2007     Adelaide Health Technology Assessment (AHTA) USCOM: Ultrasound cardiac output monitor for patients requiring haemodynamic monitoring
2006     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Use of adalimumab (Humira®) within NHS Wales
2006     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Use of agalsidase beta (Fabrazyme®) within NHS Wales
2007     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Use of alglucosidase alfa (Myozyme™) within NHS Wales
2010     HAYES, Inc. Use of anti-infliximab antibody levels to monitor infliximab treatment
2013     HAYES, Inc. Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD)
2015     HAYES, Inc. Use of anti-infliximab antibody levels to monitor infliximab treatment in patients with inflammatory bowel disease (IBD)
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Use of anti-neuronal antibodies to diagnose paraneoplastic neurological syndromes
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Use of antipsychotics and/or benzodiazepines as rapid tranquilization in inpatients of mental facilities and emergency departments: a review of the clinical effectiveness and guidelines
2005     Health Council of the Netherlands Gezondheidsraad (GR) Use of antiviral agents and other measures in an influenza pandemic
2011     Medical Services Advisory Committee (MSAC) Use of artificial disc replacement in patients with cervical degenerative disc disease
2007     Agency for Healthcare Research and Quality (AHRQ) Use of aspirin and NSAIDs to prevent colorectal cancer; an evidence synthesis
2005     Medical Advisory Secretariat (MAS) Use of automated external defibrillators in cardiac arrest - health technology literature review
2005     Medical Advisory Secretariat (MAS) Use of automated external defibrillators in cardiac arrest: an evidence-based analysis
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Use of azathioprine in adults: safety
2021     Ontario Health Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure
2009     Agency for Healthcare Research and Quality (AHRQ) Use of Bayesian techniques in randomized clinical trials: a CMS case study
2016     Technology Assessment Unit of the McGill University Health Centre (MUHC) Use of biventricular pacing in atrioventricular heart block
2005     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Use of Bortezomib (Velcade®) within NHS Wales
2007     Agency for Health Technology Assessment in Poland (AHTAPol) Use of bosentan, epoprostenol, iloprost, sildenafil and treprostinil in treatment of pulmonary arterial hypertension in Poland. Budget impact analysis.
2001     Health Technology Advisory Committee (HTAC) Use of botulinum toxin-A in pain associated with neuromuscular disorders
2003     Institute for Clinical Effectiveness and Health Policy (IECS) Use of botulinum toxine in the clinical practice
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Use of bupropion in patients with depression and the associated risk of seizures: safety
1995     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Use of calcitonin in idiopathic osteoporosis
2004     Alberta Heritage Foundation for Medical Research (AHFMR) Use of cannabis or cannabinoids for non-malignant chronic pain
2015     Agency for Healthcare Research and Quality (AHRQ) Use of cardiac resynchronization therapy in the Medicare population
2004     Technology Assessment Unit of the McGill University Health Centre (MUHC) Use of carmustine implants (GLIADEL wafer) in patients with malignant glioma at The McGill University Health Centre
1998     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Use of CDET gamma-cameras for conventional scintigraphy (systematic review, primary research, expert panel)
2006     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Use of cetuximab (Erbitux®) within NHS Wales
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Use of chlorhexidine gluconate with alcohol for the prevention of peripheral intravenous device infections: a review of clinical and cost effectiveness, and guidelines
2000     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Use of cisapride in patients with non-ulcer dyspepsia: a meta-analysis of randomized trials
2008     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) Use of class 3b and class 4 lasers and intense pulsed light sources for cosmetic procedures in non-medical settings
2009     NIHR Health Technology Assessment programme Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review
2009     NIHR Health Technology Assessment programme Use of classical and novel biomarkers as prognostic risk factors for prostate cancer: a systematic review
2010     Medical Advisory Secretariat (MAS) Use of contrast agents with echocardiography in patients with suboptimal echocardiography
2024     Belgian Health Care Knowledge Centre (KCE) Use of diagnostic immunohistochemistry and electron microscopy tests in Belgium (Study 2021-01)
2014     Blue Cross Blue Shield Association (BCBS) Use of digital breast tomosynthesis with mammography for breast cancer screening or diagnosis
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Use of diuretics for hypertension in patients with reduced renal function: a review of clinical effectiveness, safety, and guidelines
2015     NIHR Health Technology Assessment programme Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)
2002     Blue Cross Blue Shield Association (BCBS) Use of epithelial cell cytology in breast cancer risk assessment and high-risk patient management
2001     Agency for Healthcare Research and Quality (AHRQ) Use of epoetin for anemia in chronic renal failure
2017     Technology Assessment Unit of the McGill University Health Centre (MUHC) Use of extracorporeal membrane oxygenation for cardiac life support in adult subjects
2006     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) Use of FDG-PET in clinical situations not addressed in the monitorized use of this technology. IPE-06/49
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Use of fentanyl and continuous electronic fetal monitoring in labour and delivery: a review of clinical effectiveness, safety, and clinical practice guidelines
2005     Andalusian Health Technology Assessment Area (AETSA) Use of flash sterilization
2014     NIHR Health Technology Assessment programme Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey
2007     Blue Cross Blue Shield Association (BCBS) Use of GeneSearch breast lymph node assay to detect sentinel node metastases in early stage breast cancer
2003     Agency for Healthcare Research and Quality (AHRQ) Use of glycated hemoglobin and microalbuminuria in the monitoring of diabetes mellitus
2003     Norwegian Knowledge Centre for the Health Services (NOKC) Use of hematopoietic stem cells from cord blood
2007     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Use of iloprost trometamol (Ventavis®) within NHS Wales
2005     Blue Cross Blue Shield Association (BCBS) Use of implantable cardioverter-defibrillators for prevention of sudden death in patients at high risk for ventricular arrhythmia
2002     Blue Cross Blue Shield Association (BCBS) Use of implantable cardioverter-defibrillators for prevention of sudden death in patients at high risk for ventricular arrhythmia
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Use of In-111 Capromab Pendetide in detecting metastatic prostate cancer
2003     Blue Cross Blue Shield Association (BCBS) Use of intermittent or continuous interstitial fluid glucose monitoring in patients with diabetes mellitus